Portal de Periódicos da CAPES

Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico

2019; Nature Portfolio; Volume: 4; Issue: 1 Linguagem: Inglês

10.1038/s41525-018-0076-1

2056-7944

Alicia Scocchia, Kristen Wigby, Diane Masser‐Frye, Miguel Del Campo, Carolina I. Galarreta, Erin Thorpe, Julia McEachern, Keisha Robinson, Andrew M. Gross, Maren Bennett, Krista Bluske, Carolyn M. Brown, Amanda Buchanan, Brendan Burns, Nicole Burns, Anjana Chandrasekhar, Aditi Chawla, Amanda Clause, Alison J. Coffey, María Laura Cremona, Vlad Gainullin, R. Tanner Hagelstrom, Alka Malhotra, M. Naresh Kumar. K. Rajan, Revathi Rajkumar, Sarah Schmidt, Subramanian S. Ajay, Vani Rajan, Denise Perry, John W. Belmont, David Bentley, Marilyn C. Jones, Ryan J. Taft,

Genetic factors in colorectal cancer

Abstract Patients with rare, undiagnosed, or genetic disease (RUGD) often undergo years of serial testing, commonly referred to as the “diagnostic odyssey”. Patients in resource-limited areas face even greater challenges—a definitive diagnosis may never be reached due to difficulties in gaining access to clinicians, appropriate specialists, and diagnostic testing. Here, we report on a collaboration of the Illumina iHope Program with the Foundation for the Children of the Californias and Hospital Infantil de Las Californias, to enable deployment of clinical whole genome sequencing (cWGS) as first-tier test in a resource-limited dysmorphology clinic in northern Mexico. A total of 60 probands who were followed for a suspected genetic diagnosis and clinically unresolved after expert examination were tested with cWGS, and the ordering clinicians completed a semi-structured survey to investigate change in clinical management resulting from cWGS findings. Clinically significant genomic findings were identified in 68.3% ( n = 41) of probands. No recurrent molecular diagnoses were observed. Copy number variants or gross chromosomal abnormalities accounted for 48.8% ( n = 20) of the diagnosed cases, including a mosaic trisomy and suspected derivative chromosomes. A qualitative assessment of clinical management revealed 48.8% ( n = 20) of those diagnosed had a change in clinical course based on their cWGS results, despite resource limitations. These data suggest that a cWGS first-tier testing approach can benefit patients with suspected genetic disorders.